Spruce Street Capital LP 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Spruce Street Capital LP disclosed 28 US equity positions worth $415.9m in its Q1 2026 13F filing. The largest position was RLMD at 10.3% of the reported book, followed by KINIKSA PHARMACEUTICALS I and LB PHARMACEUTICALS INC.
What did Spruce Street Capital LP own in Q1 2026? Top 28 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 10.3% | $43.0m | 6,262,114 | – | |
| 2 | KINIKSA PHARMACEUTICALS I | 8.8% | $36.6m | 761,063 | – | ||
| 3 | LB PHARMACEUTICALS INC | 8.1% | $33.6m | 1,376,159 | – | ||
| 4 | DNTH DIANTHUS THERAPEUTICS IN | Healthcare | 7.5% | $31.3m | 373,274 | – | |
| 5 | RLAY RELAY THERAPEUTICS INC | Healthcare | 7.1% | $29.7m | 2,984,125 | – | |
| 6 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 7.0% | $29.1m | 1,325,210 | – | |
| 7 | CNTA CENTESSA PHARMACEUTICALS | 4.7% | $19.5m | 489,849 | – | ||
| 8 | SVRA SAVARA INC | Healthcare | 4.4% | $18.5m | 3,383,175 | – | |
| 9 | 4XC1 KALVISTA PHARMACEUTICALS | 4.3% | $18.1m | 897,681 | – | ||
| 10 | PCVX VAXCYTE INC | Healthcare | 3.4% | $14.3m | 245,709 | – | |
| 11 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.1% | $12.9m | 329,006 | – | |
| 12 | SRZN SURROZEN INC COM NEW | 3.0% | $12.6m | 432,040 | – | ||
| 13 | ENTA ENANTA PHARMACEUTICALS I | Healthcare | 2.8% | $11.8m | 932,598 | – | |
| 14 | ALKS ALKERMES PLC | Healthcare | 2.7% | $11.2m | 317,992 | – | |
| 15 | CATX PERSPECTIVE THERAPEUTICS | 2.6% | $11.0m | 2,627,107 | – | ||
| 16 | NERV MINERVA NEUROSCIENC | 2.4% | $10.0m | 1,655,500 | – | ||
| 17 | IPSC CENTURY THERAPEUTICS | Healthcare | 2.2% | $9.2m | 4,059,054 | – | |
| 18 | ALMS ALUMIS INC | Healthcare | 2.1% | $8.6m | 392,574 | – | |
| 19 | SABS SAB BIOTHERAPEUTICS IN | 2.0% | $8.4m | 2,198,502 | – | ||
| 20 | ERAS ERASCA INC | Healthcare | 1.6% | $6.8m | 422,543 | – | |
| 21 | IKT INHIBIKASE THERAPEUTI | 1.4% | $6.0m | 3,581,603 | – | ||
| 22 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.4% | $6.0m | 200,000 | – | |
| 23 | ANTX AN2 THERAPEUTICS INC | 1.3% | $5.6m | 1,661,073 | – | ||
| 24 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 1.3% | $5.3m | 928,593 | – | |
| 25 | HELIX ACQUISITION CORP III | 1.2% | $5.1m | 500,000 | – | ||
| 26 | ALEC ALECTOR INC | Healthcare | 1.1% | $4.5m | 2,101,068 | – | |
| 27 | LONA LEONABIO INC | 0.9% | $3.8m | 393,701 | – | ||
| 28 | CRVS CORVUS PHARMACEUTICALS I | Healthcare | 0.8% | $3.4m | 231,585 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.